Investors

Corporate Profile

Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Founded in 1996, the Company is publicly traded on the NASDAQ Global Market under the ticker symbol SBBP.

| (Common Stock)

Stock chart for: SBBP.O. Currently trading at $4.40 with a 52 week high of $6.24 and a 52 week low of $2.00.

Data provided by Nasdaq. Minimum 15 minutes delayed.

Press Releases

Strongbridge Biopharma plc to Present at Two Upcoming Investor Conferences

11/12/19

DUBLIN, Ireland and TREVOSE, Pa. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc , (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that...

Read More
Strongbridge Biopharma plc Reports Third Quarter 2019 Financial Results and Provides Corporate Update

11/07/19

~ KEVEYIS ® (dichlorphenamide) Achieved $5.7 Million in Revenue Along with a Positive Contribution Margin in Third Quarter of 2019; Strongbridge Remains On-Track to Meet or Exceed the Top End of Full-Year KEVEYIS Revenue Guidance of $18 Million to $20 Million ~ ~ Phase 3 LOGICS Study of R ECORLEV™...

Read More

Investors

Investors

Corporate Profile

Press Releases

Strongbridge Biopharma plc to Present at Two Upcoming Investor Conferences

Strongbridge Biopharma plc Reports Third Quarter 2019 Financial Results and Provides Corporate Update

Upcoming Events